The receipt of IRB approval is a necessary step that will allow
An IRB is an FDA-registered consortium that has been formally designated to review and monitor biomedical research involving human subjects. IRB approval is a critical and necessary prerequisite to commencing human clinical trials and serves an important role in the protection of the rights and welfare of human research subjects.
'We are pleased to announce the expeditious receipt of this vital next step in commencing the clinical trial for CELZ-201-DDT,' said
About CELZ-201-DDT
CELZ-201-DDT is a patented procedure that utilizes an 'off the shelf, ready-to-use' universal and proprietary allogenic (donor) cell line developed by the Company and trademarked as AlloStem. Using an ultrasound guided, non-surgical procedure, AlloStem is injected in areas surrounding the diseased disc(s), thereby potentially repairing, remodeling, and improving the blood supply around the disc and lower back area, without exposing the patient to radiation as with other cell-based procedures. CELZ-201-DDT distinguishes itself by using a unique immunomodulatory formula derived from allogeneic perinatal cells, which in preliminary studies have shown potential for tissue repair and changing cytokine profiles.
About
Special Note Regarding Forward Looking Statements
NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Contact:
Email: IR@CreativeMedicalTechnology.com
(C) 2023 Electronic News Publishing, source